Abstracts tagged "Disease-Modifying Antirheumatic Drugs (Dmards)"

Abstract Number: 0212 • ACR Convergence 2023
The Impact of Immunosuppression on the Humoral Immunogenicity of SARS-CoV-2 mRNA Vaccines in SLE
Rebecca Sadun¹, Dan Crair², Emmanuel B Walter³, Jennifer Rogers¹, Megan Clowse⁴, Amanda Eudy⁵, Kai Sun¹, Jayanth Doss¹, Lisa Criscione-Schreiber⁶, Sarah Valencia² and M. Anthony Moody⁶, ¹Duke University, Durham, NC, ²Duke Human Vaccine Institute, Durham, NC, ³Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC, ⁴Duke University, Chapel Hill, NC, ⁵Duke University, Raleigh, NC, ⁶Duke University School of Medicine, Durham, NC
Background/Purpose: The ACR's COVID-19 Vaccine Guidance recommends all patients with rheumatic diagnoses be vaccinated against SARS-CoV-2. The predominant SARS-CoV-2 vaccines used in the United States…
Abstract Number: 0430 • ACR Convergence 2023
A Multicenter, Real-world Clinical Data Study of the Use of JAK Kinase Inhibitors in a Large Cohort of Patients with Rheumatoid Arthritis
Maria Lopez-Lasanta¹, Helena Borrell¹, Meritxell Salles Lizarzaburu², Virginia Ruiz-Esquide³, Daniel Roig⁴, Annika Nack⁵, Carolina Pérez⁶, Julia Bernardez⁷, Andrea García⁸, Joana Rovira⁹, Andrea Cuervo¹⁰, Marta Valls¹¹, Carmen Garcia¹², Sonia Minguez¹³, Rosa Morla¹⁴, Paula Estrada⁴, Melania Martinez¹⁵, Conxita Pitarch¹⁶, Noemi Busquets¹⁷, Hye Park¹⁸, Jose A Gomez-Puerta¹⁹, Susana Holgado²⁰, Nuria Montala²¹, Raimon Sanmarti³, Lourdes Mateo²⁰, Cesar Diaz²², Hector Corominas²³ and Georgina Salvador⁷, ¹Hospital Universitari Vall d'Hebron, Rheumatology, Barcelona, Spain, ²C. H. de Manresa - Fundació Althaia, Barcelona, Spain, ³Hospital Clinic, Rheumatology, Barcelona, Spain, ⁴Hospital Moisses Broggi, Rheumatology, Barcelona, Spain, ⁵Department of Rheumatology, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain, ⁶Hospital del Mar-Parc de Salut Mar, Rheumatology, Barcelona, Spain, ⁷Hospital Mutua Terrassa, Rheumatology, Barcelona, Spain, ⁸Hospital Sant Pau-Dos de Maig, Rheumatology, Barcelona, Spain, ⁹Hospital de Mollet, Barcelona, Spain, ¹⁰Hospital Granollers, Rheumatology, Barcelona, Spain, ¹¹Hospital Josep Trueta, Rheumatology, Girona, Spain, ¹²Hospital de Terrassa, Rheumatology, Barcelona, Spain, ¹³Fundació Althaia, Manresa, Spain, ¹⁴Hospital Clinic, Rheumatology, Barcelona, Barcelona, Spain, ¹⁵Hospital Germans Trias i Pujol, Rheumatology, Barcelona, Spain, ¹⁶Hospital Universitari de la Santa Creu i Sant Pau, Rheumatology, Barcelona, Spain, ¹⁷HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, ¹⁸Hospital Universitari Sant Pau, Rheumatology, Barcelona, Spain, ¹⁹Department of Rheumatology, Hospital Clinic of Barcelona, Barcelona, Spain, ²⁰Hospital Universitari Germans Trias i Pujol, Rheumatology, Barcelona, Spain, ²¹Hospital Santa Maria, Rheumatology, Lleida, Spain, ²²Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, ²³Hospital Universitario Sant Pau, Rheumatology, Barcelona, Spain
Background/Purpose: The Janus Kinase inhibitors (JAKi) drugs are approved for use in adults with moderate to severe rheumatoid arthritis (RA). Real-world studies are necessary as…
Abstract Number: 0534 • ACR Convergence 2023
Tapering Tofacitinib for Axial Spondyloarthritis in Remission or Low-disease Activity State
Pankti Mehta¹, Sanjo Saijan², Justin George², Sakir Ahmed³, Bhowmik Meghnathi⁴ and Padmanabha Shenoy², ¹King George's Medical University, Mumbai, India, ²Centre for arthritis and rheumatism excellence, Kochi, India, ³Kalinga Institute of Medical Sciences, Bhubaneswar, India, ⁴Smt. NHL Municipal Medical College and SVP hospital, CIMS Hospital, Ahmedabad, India
Background/Purpose: The recent recommendations from EULAR-ASAS for Axial Spondyloarthritis (AxSpA) call for decreasing biologic (b)DMARDs after an extended period of remission. This is especially relevant…
Abstract Number: 1107 • ACR Convergence 2023
Predictors of Pegloticase Urate-lowering Response in the Presence and Absence of Methotrexate Co-therapy
James Mossell¹, Mai Duong², Katie Obermeyer², Lissa Padnick-Silver², Brian LaMoreaux² and Sanjay Chabra³, ¹Arthritis and Osteoporosis Center of South Georgia, Tifton, GA, ²Horizon Therapeutics, Deerfield, IL, ³Texas Arthritis Center, El Paso, TX
Background/Purpose: Pegloticase can lower serum urate (SU) in patients with uncontrolled gout who are refractory to/intolerant of oral urate-lowering therapies. However, antidrug antibodies (ADAs) can…
Abstract Number: 1423 • ACR Convergence 2023
Impact of Upadacitinib on Enthesitis and Dactylitis by Location in Patients with Psoriatic Arthritis and an Inadequate Response to Biologic DMARDs from the SELECT-PsA 2 Trial
Laura Coates¹, Catherine Bakewell², Majed Khraishi³, Shirley Chen⁴, Tianming Gao⁴, Arathi Setty⁴, Heather Jones⁵, Sandra Ciecinski⁴ and Eduardo Mysler⁶, ¹University of Oxford, Oxford, United Kingdom, ²Intermountain Healthcare Medical Group, Salt Lake City, UT, ³Memorial University of Newfoundland, St. John's, NL, Canada, ⁴AbbVie, Inc., North Chicago, IL, ⁵AbbVie, Inc., Mettawa, IL, ⁶Organización Medica de Investigación, Buenos Aires, Argentina
Background/Purpose: Enthesitis and dactylitis are associated with reduced quality of life and greater impairment in daily activities. In the SELECT-PsA 2 phase 3 trial, the…
Abstract Number: 2007 • ACR Convergence 2023
Effects of IL-17 Blockade on Skeletal Microarchitecture in Patients with Axial Spondyloarthritis: An HR-pQCT Study
Insa Mannstadt, Donald McMahon, Douglas Mintz, Weija Yuan, Linda Russell, Susan Goodman, Emily Stein and Dalit Ashany, Hospital for Special Surgery, New York, NY
Background/Purpose: Axial spondyloarthritis (AxSpA), a chronic inflammatory rheumatic disease causes abnormal bone growth at the spine and paradoxically has been linked to osteoporosis and fragility…
Abstract Number: 2218 • ACR Convergence 2023
Exploring Metabolite Markers Associated with Treatment Response of Biologic Disease Modifying Antirheumatic Drugs in Psoriatic Arthritis Patients
John Koussiouris¹, Nikita Looby¹, Max Kotlyar², Vathany Kulasingam³, Igor Jurisica⁴, Ashish J Mathew⁵, Proton Rahman⁶ and Vinod Chandran⁷, ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ²Osteoarthritis Research Program, Division of Orthopaedic Surgery, Schroeder Arthritis Institute and Data Science Discovery Centre for Chronic diseases, Krembil Research Institute, Toronto, ON, Canada, ³Department of Laboratory Medicine and Pathobiology, University of Toronto and Division of Clinical Biochemistry, Laboratory Medicine Program, University Health Network, Toronto, ON, Canada, ⁴Schroeder Arthritis Institute, Krembil Research Institute and Departments of Medical Biophysics and Computer Science and Faculty of Dentistry, University of Toronto and Institute of Neuroimmunology, Slovak Academy of Sciences, Bratislava, Slovakia, ⁵Christian Medical College, Vellore, India, ⁶Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, ⁷Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and Division of Rheumatology, Department of Medicine, University of Toronto, Toronto, ON, Canada
Background/Purpose: The use of biologic disease-modifying anti-rheumatic drugs (bDMARDS) is the current standard of care for severe diseases like psoriatic arthritis (PsA) which affects approximately…
Abstract Number: 2547 • ACR Convergence 2023
Characteristics of Difficult-To-Treat Axial Spondyloarthritis: Results of a Multicentric Retrospective Study
Cecile PHILIPPOTEAUX¹, Thibaut DELEPINE², Emeline Cailliau¹, Peggy Philippe¹, Nicolas TAISNE³, Tristan Pascart⁴, Julien Paccou¹, Bernard Cortet¹, Rene-Marc Flipo¹ and Jean-Guillaume Letarouilly⁵, ¹University Hospital Center of Lille, Lille, France, ²CHU de Lille, Lille University Hospital, Valenciennes, France, ³Valenciennes Hospital Center, Valenciennes, France, ⁴Department of Rheumatology, Saint-Philibert Hospital, Lille Catholic University, Lille, France, ⁵CHU Lille, Lille, France
Background/Purpose: The EULAR task force recently published the difficult-to-treat (D2T) RA definition1, however, a definition of D2T axSpA is still lacking. To date, we have…
Abstract Number: 0224 • ACR Convergence 2023
Risk Factors and Outcomes for Repeat COVID-19 Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Case-control Study
Emily Kowalski¹, Xiaosong Wang¹, Naomi Patel², Yumeko Kawano¹, Claire Cook², Kathleen Vanni¹, Grace Qian¹, Katarina Bade³, Shruthi Srivatsan², Zachary Williams², Zachary Wallace⁴ and Jeffrey Sparks⁵, ¹Brigham and Women's Hospital, Boston, MA, ²Massachusetts General Hospital, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Newton, MA, ⁵Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA
Background/Purpose: As initial COVID-19 infections become nearly ubiquitous and the available prevention and treatment strategies evolve, patients with systemic autoimmune rheumatic diseases (SARDs) may be…
Abstract Number: 0433 • ACR Convergence 2023
DMARD Initiation in Older Adults with New Diagnosis of Late-Onset Rheumatoid Arthritis
Jiha Lee¹, Jonathan Martindale¹, Una Makris², Namrata Singh³, Raymond Yung⁴ and Julie Bynum¹, ¹University of Michigan, Ann Arbor, MI, ²UT Southwestern Medical Center and Dallas VA, Dallas, TX, ³University of Washington, Bellevue, WA, ⁴Michigan Medicine, Ann Arbor, MI
Background/Purpose: The number of older adults living with rheumatoid arthritis (RA) is growing as the world population is aging. Up to one-third of the older…
Abstract Number: 0538 • ACR Convergence 2023
The Challenge of Identifying Difficult-To-Treat Axial Spondyloarthritis in Clinical Practice: Results from La Paz-SpA Cohort
Manuel Juárez¹, Diego Benavent², Victoria Navarro-Compán³, Mariana Díaz-Almirón⁴, Marta Novella-Navarro⁵, Diana Peiteado¹, Alejandro Villalba¹, Irene Monjo⁶, Laura Nuño⁷, Alejandro Balsa⁵ and Chamaida Plasencia-Rodríguez⁵, ¹Rheumatology Department, La Paz University Hospital, Madrid, Spain, ²Hospital la Paz, Madrid, Spain, ³Department of Rheumatology, La Paz University Hospital, IdiPaz, Madrid, Spain, ⁴Biostatistics Unit, IdiPAZ, La Paz University Hospital, Madrid, Spain, ⁵Hospital Universitario La Paz, Madrid, Spain, ⁶University Hospital La Paz, Madrid, Spain, ⁷Hospital Universitario La Paz - IdiPAZ, Madrid, Spain
Background/Purpose: Despite multiple pharmacological options for axSpA are available, still one out of three patients do not achieve the recommended treatment target (1), highlighting the…
Abstract Number: 1123 • ACR Convergence 2023
Real-world Trends in the Use of Immunomodulation as Co-therapy to Pegloticase: Claims-based Findings Since 2016
John Botson¹, Qianhong Fu², Kaiding Zhu², Lissa Padnick-Silver² and Brian LaMoreaux², ¹Orthopedic Physicians Alaska, Anchorage, AK, ²Horizon Therapeutics, Deerfield, IL
Background/Purpose: Pegloticase can treat uncontrolled gout but anti-drug antibodies limit urate-lowering response and put patients at risk for infusion reactions (IRs).1, 2 The first case…
Abstract Number: 1425 • ACR Convergence 2023
Efficacy and Safety of Tofacitinib in an Open-Label, Long-Term Extension Study in Patients with Psoriatic Arthritis Who Received Adalimumab or Tofacitinib in a Phase 3 Randomized Controlled Study: A Post Hoc Analysis
Dafna Gladman¹, Peter Nash², Philip J. Mease³, Oliver FitzGerald⁴, Karim R. Masri⁵, Stephanie Duench⁶ and Mary Jane Cadatal⁷, ¹Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²School of Medicine, Griffith University, Brisbane, Australia, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA, ⁴Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ⁵Pfizer Inc., Collegeville, PA, ⁶Pfizer Inc., New York, NY, ⁷Pfizer Inc., Manila, Philippines
Background/Purpose: Patients (pts) with PsA and an inadequate response (IR) to conventional synthetic DMARDs are routinely treated with TNF inhibitors (TNFi).1,2 Intolerance/IR to TNFi may…
Abstract Number: 2021 • ACR Convergence 2023
Beliefs, Attitudes, and Preferences of Patients with Rheumatoid Arthritis (RA) and Concomitant Cancer with Respect to RA Therapy
Juan Ruiz¹, Sheneze Madramootoo², Maria A. Lopez-Olivo¹, Namrata Singh³ and Maria Suarez-Almazor⁴, ¹The University of Texas, MD Anderson Cancer Center, Houston, TX, ²The University of Texas MD Anderson Cancer Center, Houston, TX, ³University of Washington, Bellevue, WA, ⁴MD Anderson Cancer Center, Houston, TX
Background/Purpose: Treatment of rheumatoid arthritis (RA) in patients with cancer could potentially result in poor cancer outcomes because of immunosuppression. Adequate data for shared decision-making…
Abstract Number: 2227 • ACR Convergence 2023
The Impact of Smoking Status on One Year Secukinumab Retention Rate in 1,684 Patients with PsA: Real-World Results from the EuroSpA Collaboration
Zohra Faizy Ahmadzay¹, Stylianos Georgiadis², Marion Pons², Merete Hetland², Bente Glintborg³, Jette Heberg², Sara Nysom Christiansen², Simon Horskjær Rasmussen², Anne Gitte Loft⁴, Isabel Castrejon⁵, Lucia Otero-Valera⁶, Jakub Zavada⁷, Karel Pavelka⁸, Heikki Relas⁹, Laura Kuusalo¹⁰, Burkhard Moeller¹¹, Michael Nissen¹², Ziga Rotar¹³, Katja Perdan Pirkmajer¹⁴, Daniela Santos Oliveira¹⁵, Ana Rita Cruz-Machado¹⁶, Brigitte Michelsen¹⁷, Eirik Kristianslund¹⁸, Bjorn Gudbjornsson¹⁹, Gerdur Maria Grondal²⁰, Karin Laas²¹, Pasoon Hellamand²², Ismail Sari²³, Daniela Di Giuseppe²⁴, Mikkel Østergaard²⁵ and Lykke Ørnbjerg², ¹Rigshospitalet Glostrup, University of Copenhagen, Glostrup, Denmark, ²Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ³Rigshospitalet Glostrup, University of Copenhagen, Virum, Denmark, ⁴Aarhus University, Horsens, Denmark, ⁵Hospital General Universitario Gregorio Marañón, Madrid, Spain, ⁶Spanish Society of Rheumatology, Madrid, Spain, ⁷Institute of Rheumatology; Charles University, Prague, Czech Republic, ⁸Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ⁹Helsinki University Hospital, Helsinki, Finland, ¹⁰Division of Internal Medicine, Centre for Rheumatology and Clinical Immunology, University of Turku and Turku University Hospital, Turku, Finland, ¹¹Inselspital - University Hospital Bern, Bern, Switzerland, ¹²Geneva University Hospitals, Geneva, Switzerland, ¹³University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁴Department of Rheumatology, University Medical Centre LJubljana, Ljubljana, Slovenia, ¹⁵Department of Medicine, Faculty of Medicine, University of Porto, Rheumatology Department, Centro Hospitalar e Universitário de São João, Porto, Portugal, ¹⁶Rheumatology and Metabolic Bone Diseases Department, Hospital de Santa Maria, CHULN, Academic Medical Center and ERN-ReCONNET; Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina da Universidade de Lisboa; Reuma.pt Sociedade Portuuesa de Reumatologia, Lisbon, Portugal, ¹⁷Rigshospitalet Glostrup; Diakonhjemmet Hospital; Sørlandet Hospital, Copenhagen, Denmark, ¹⁸Diakonhjemmet Hospital, Oslo, Norway, ¹⁹Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ²⁰Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ²¹Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia, ²²Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ²³Division of Rheumatology, Department of Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey, ²⁴Karolinska Institutet, Stockholm, Sweden, ²⁵Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: Smoking has been associated with higher disease activity, poorer treatment response, and drug retention rate among psoriatic arthritis (PsA) patients treated with Tumor Necrosis…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].